236 related articles for article (PubMed ID: 26776867)
1. A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis.
Brims FJ; Meniawy TM; Duffus I; de Fonseka D; Segal A; Creaney J; Maskell N; Lake RA; de Klerk N; Nowak AK
J Thorac Oncol; 2016 Apr; 11(4):573-82. PubMed ID: 26776867
[TBL] [Abstract][Full Text] [Related]
2. Prediction modelling using routine clinical parameters to stratify survival in Malignant Pleural Mesothelioma patients undergoing cytoreductive surgery.
Harris EJA; Kao S; McCaughan B; Nakano T; Kondo N; Hyland R; Nowak AK; de Klerk NH; Brims FJH
J Thorac Oncol; 2019 Feb; 14(2):288-293. PubMed ID: 30366103
[TBL] [Abstract][Full Text] [Related]
3. The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study.
Zauderer MG; Martin A; Egger J; Rizvi H; Offin M; Rimner A; Adusumilli PS; Rusch VW; Kris MG; Sauter JL; Ladanyi M; Shen R
Lancet Digit Health; 2021 Sep; 3(9):e565-e576. PubMed ID: 34332931
[TBL] [Abstract][Full Text] [Related]
4. Malignant pleural mesothelioma: diagnostic value of medical thoracoscopy and long-term prognostic analysis.
Xu LL; Yang Y; Wang Z; Wang XJ; Tong ZH; Shi HZ
BMC Pulm Med; 2018 Apr; 18(1):56. PubMed ID: 29615010
[TBL] [Abstract][Full Text] [Related]
5. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G
Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
[TBL] [Abstract][Full Text] [Related]
6. Stratification of malignant pleural mesothelioma prognosis using recursive partitioning analysis.
Suzuki H; Asami K; Hirashima T; Okamoto N; Yamadori T; Tamiya M; Morishita N; Shiroyama T; Takeoka S; Osa A; Azuma Y; Okishio K; Kawaguchi T; Atagi S; Kawase I
Lung; 2014 Feb; 192(1):191-5. PubMed ID: 24141556
[TBL] [Abstract][Full Text] [Related]
7. Predicting survival in malignant pleural mesothelioma using routine clinical and laboratory characteristics.
Gunatilake S; Lodge D; Neville D; Jones T; Fogg C; Bassett P; Begum S; Kerley S; Marshall L; Glaysher S; Elliott S; Stores R; Bishop L; Chauhan A
BMJ Open Respir Res; 2021 Jan; 8(1):. PubMed ID: 33414260
[TBL] [Abstract][Full Text] [Related]
8. The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma.
Proto C; Signorelli D; Mallone S; Prelaj A; Lo Russo G; Imbimbo M; Galli G; Ferrara R; Ganzinelli M; Leuzzi G; Greco FG; Calareso G; Botta L; Gatta G; Garassino M; Trama A
Clin Lung Cancer; 2019 Nov; 20(6):e652-e660. PubMed ID: 31377142
[TBL] [Abstract][Full Text] [Related]
9. Sarcomatoid mesothelioma: future advances in diagnosis, biomolecular assessment, and therapeutic options in a poor-outcome disease.
Galetta D; Catino A; Misino A; Logroscino A; Fico M
Tumori; 2016; 102(2):127-30. PubMed ID: 26108245
[TBL] [Abstract][Full Text] [Related]
10. Pathologic Grading of Malignant Pleural Mesothelioma: An Evidence-Based Proposal.
Pelosi G; Papotti M; Righi L; Rossi G; Ferrero S; Bosari S; Calabrese F; Kern I; Maisonneuve P; Sonzogni A; Albini A; Harari S; Barbieri F; Capelletto E; Catino AM; Cavone D; De Palma A; Fusco N; Lunardi F; Maiorano E; Marzullo A; Novello S; Papanikolaou N; Pasello G; Pennella A; Pezzuto F; Punzi A; Prisciandaro E; Rea F; Rosso L; Scattone A; Serio G
J Thorac Oncol; 2018 Nov; 13(11):1750-1761. PubMed ID: 30249391
[TBL] [Abstract][Full Text] [Related]
11. Survival analysis via nomogram of surgical patients with malignant pleural mesothelioma in the Surveillance, Epidemiology, and End Results database.
Zhuo M; Zheng Q; Chi Y; Jia B; Zhao J; Wu M; An T; Wang Y; Li J; Zhao X; Yang X; Zhong J; Chen H; Dong Z; Wang J; Zhai X; Wang Z
Thorac Cancer; 2019 May; 10(5):1193-1202. PubMed ID: 30951250
[TBL] [Abstract][Full Text] [Related]
12. Detection of circulating tumour cells in peripheral blood of patients with malignant pleural mesothelioma.
Raphael J; Massard C; Gong IY; Farace F; Margery J; Billiot F; Hollebecque A; Besse B; Soria JC; Planchard D
Cancer Biomark; 2015; 15(2):151-6. PubMed ID: 25519011
[TBL] [Abstract][Full Text] [Related]
13. A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.
Kataoka Y; Yamamoto Y; Otsuki T; Shinomiya M; Terada T; Fukuma S; Yamazaki S; Hirabayashi M; Nakano T; Fukuhara S
Jpn J Clin Oncol; 2015 Jun; 45(6):562-8. PubMed ID: 25838292
[TBL] [Abstract][Full Text] [Related]
14. Survival results in biphasic malignant pleural mesothelioma patients: A multicentric analysis.
Lococo F; Torricelli F; Lang-Lazdunski L; Veronesi G; Rena O; Paci M; Casadio C; Piana S; Novellis P; Di Stefano TS; Ciarrocchi A; Billè A
J Thorac Cardiovasc Surg; 2020 Apr; 159(4):1584-1593.e2. PubMed ID: 31590954
[TBL] [Abstract][Full Text] [Related]
15. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma.
McGregor SM; Dunning R; Hyjek E; Vigneswaran W; Husain AN; Krausz T
Hum Pathol; 2015 Nov; 46(11):1670-8. PubMed ID: 26376834
[TBL] [Abstract][Full Text] [Related]
16. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors and treatment outcomes of malignant pleural mesothelioma in Eastern Asian patients - A Taiwanese study.
Wu TH; Lee LJ; Yuan CT; Chen TW; Yang JC
J Formos Med Assoc; 2019 Jan; 118(1 Pt 2):230-236. PubMed ID: 29709339
[TBL] [Abstract][Full Text] [Related]
18. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.
de Reyniès A; Jaurand MC; Renier A; Couchy G; Hysi I; Elarouci N; Galateau-Sallé F; Copin MC; Hofman P; Cazes A; Andujar P; Imbeaud S; Petel F; Pairon JC; Le Pimpec-Barthes F; Zucman-Rossi J; Jean D
Clin Cancer Res; 2014 Mar; 20(5):1323-34. PubMed ID: 24443521
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in malignant pleural mesothelioma: a retrospective study of 60 Turkish patients.
Koyuncu A; Koksal D; Ozmen O; Demirag F; Bayiz H; Aydogdu K; Berkoglu M
J Cancer Res Ther; 2015; 11(1):216-22. PubMed ID: 25879365
[TBL] [Abstract][Full Text] [Related]
20. Disparities in Compliance With National Guidelines for the Treatment of Malignant Pleural Mesothelioma.
Espinoza-Mercado F; Borgella JD; Berz D; Alban RF; Sarkissian A; Imai HTA; Soukiasian HJ
Ann Thorac Surg; 2019 Sep; 108(3):889-896. PubMed ID: 31004585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
